H-2 Antigens pp 691-697 | Cite as

In Vivo Antitumor Effects of Anti-I-A Antibodies

  • Sandra H. Bridges
  • Dan L. Longo
Part of the NATO ASI Series book series (NSSA, volume 144)


In addition to their expression on various normal cells of the immune system, la molecules are present on a variety of neoplastic cells, most importantly for the work described here on the surface of virtually all B-cell lymphomas and leukemias1. As an extension of our previous studies2–4 on the in vivo effects of I-A-specific monoclonal antibodies (Mab), we have investigated their effects on an I-A-bearing B cell lymphoma. Differential effects on normal and neoplastic cells were observed, suggesting that Ia molecules on neoplastic cells are excellent targets for antibody attack in vivo.


Spleen Cell Antibody Dependent Cellular Cytotoxicity L10A Cell Antigen Present Cell Activity Spleen Colony 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    A. S. Freedman and L. M. Nadler, Cell surface markers in hematologic malignancies, Sem. Oncol. 14: 193 (1987).Google Scholar
  2. 2.
    A. M. Kruisbeek, J. J. Mond, B. J. Fowlkes, J. A. Carmen, S. Bridges, and D. L. Longo, Absence of the Lyt2,L3T4+ lineage of T cells in mice treated neonatally with anti-I-A correlates with absence of intrathymic I-A-bearing antigen-presenting cell function, J. Exp. Med. 161: 1029 (1985).PubMedCrossRefGoogle Scholar
  3. 3.
    A. M. Kruisbeek, S. Bridges, J. Carmen, D. L. Longo, and J. J. Mond, In vivo treatment of neonatal mice with anti-I-A antibodies interferes with the development of the class I, class II, and Mls-reactive proliferating T cell subset, J. Immunol. 134:3597 (1985).PubMedGoogle Scholar
  4. 4.
    A. M. Kruisbeek, J. A. Titus, D. A. Stephany, B. L. Cause, and D. L. Longo, In vivo treatment with monoclonal anti-I-A antibodies: disappearance of splenic antigen-presenting cell function concomitant with modulation of splenic cell surface I-A and I-E antigens, J. Immunol. 134:3605 (1985).PubMedGoogle Scholar
  5. 5.
    E. Walker, N. L. Warner, R. Chesnut, J. Kappler, and P. Marrack, Antigen-specific, I region-restricted interactions in vitro between tumor cell lines and T-cell hybridomas, J. Immunol. 128: 2164 (1982).PubMedGoogle Scholar
  6. 6.
    L. H. Glimcher, K. J. Kim, I. Green, and W. E. Paul, Ia antigen-bearing B cell tumor lines can present protein antigen and alloantigen in a major histocompatibility complex-restricted fashion to antigen-reactive T-cells, J. Exp. Med. 155: 445 (1982).PubMedCrossRefGoogle Scholar
  7. 7.
    M. Daley, S. H. Bridges, and R. G. Lynch, Plasmacytoma spleen colonization: a sensitive in vivo assay for idiotype-specific immune sup-pression, J. Immunol. Methods 24: 47 (1978).PubMedCrossRefGoogle Scholar
  8. 8.
    S. H. Bridges, C. Le Guern, and C. Gurgo, Inhibition of in vivo growth of murine plasmacytoma MOPC-460 by monoclonal anti-idiotypic anti-bodies directed at distinct idiotypes of the immunoglobulin on the surface of MOPC-460, Cancer Res. 44: 5051 (1984).PubMedGoogle Scholar
  9. 9.
    T. Meeker, J. Lowder, M. L. Cleary, S. Stewart, R. Warnke, J. Sklar, and R. Levy, Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies, N. Engl. J. Med. 312: 1658 (1985).PubMedCrossRefGoogle Scholar
  10. 10.
    C. C. Badger and I. D. Bernstein, Therapy of murine leukemia with mono-clonal antibody against a normal differentiation antigen, J. Exp. Med. 157: 828 (1983).PubMedCrossRefGoogle Scholar
  11. 11.
    S. Habu, J. Fukui, K. Shimamura, M. Kasai, Y. Nagai, K. Okumura, and N. Tamaoki, In vivo effects of anti-asialo GM1. 1. Reduction of NK activity and enhancement of transplanted tumor growth in nude mice, J. Immunol. 127:34 (1981).PubMedGoogle Scholar
  12. 12.
    M. Kasai, T. Yoneda, S. Habu, U. Maruyama, K. Okumura, and T. Tokunaga, In vivo effect of anti-asialo GM1 antibody on natural killer activity, Nature 291:334 (1981).PubMedCrossRefGoogle Scholar
  13. 13.
    S. Forsgren, G. Pobor, A. Coutinho, and M. Pierres, The role of I-A/E molecules in B lymphocyte activation. I. Inhibition of lipopolysaccharide induced responses by monoclonal antibodies, J. Immunol. 133: 2104 (1984).PubMedGoogle Scholar
  14. 14.
    L. Clement, T. F. Tedder, and G. L. Gartland, Antibodies reactive with class II antigens encoded for by the major histocompatibility complex inhibit human B cell activation, J. Immunol. 136: 2375 (1986).PubMedGoogle Scholar
  15. 15.
    R. Palacios, O. Martinez-Maza, and K. Guy, Monoclonal antibodies against HLA-DR antigens replace T helper cells in activation of B lymphocytes, Proc. Natl. Acad. Sci. USA 80: 3456 (1983).PubMedCrossRefGoogle Scholar
  16. 16.
    G. B. Bishop and G. Haughton, Induced differentiation of a transformed clone of Ly-1+ B cells by clonal T cells and antigen, Proc. Natl. Acad. Sci. USA 83: 7410 (1986).PubMedCrossRefGoogle Scholar
  17. 17.
    Z. Z. Chen, J. C. McGuire, K. L. Leach, and J. C. Cambier, Trans-membrane signaling through B cell MHC class II molecules: anti-Ia antibodies induce protein kinase C translocation to the nuclear fraction, J. Immunol. 138: 2345 (1987).PubMedGoogle Scholar
  18. 18.
    J. D. Ashwell, D. L. Longo, and S. H. Bridges, T-cell tumor elimination as a result of T-cell receptor-mediated activation, Science 237: 61 (1987).PubMedCrossRefGoogle Scholar
  19. 19.
    M. Mercep, J. J. Sussman, and J. D. Ashwell, Stimulation of murine T cell hybridomas with anti-Thy-1 monoclonal antibodies results in IL-2 production and inhibition of growth, Fed. Proc. 46: 1051 (1987).Google Scholar
  20. 20.
    E. S. Vitetta, K. Brooks, P. Isakson, J. Layton, E. Pure, and D. Yuan, Blymphocyte receptors, In: “Fundamental Immunology,” W. Paul, ed., Raven Press, New York (1984).Google Scholar
  21. 21.
    P. C. Isakson, K. A. Krolick, J. W. Uhr, and E. S. Vitetta, The effect of anti-immunoglobulin antibodies on the in vitro proliferation and differentiation of normal and neoplastic murine B cells, J. Immunol. 125: 886 (1980).PubMedGoogle Scholar
  22. 22.
    A. W. Boyd and J. W. Schrader, The regulation of growth and differentiation of a murine B cell lymphoma, J. Immunol. 126: 2466 (1981).PubMedGoogle Scholar
  23. 23.
    D. W. Scott, D. Livnat, C. A. Pennell, and P. Keng, Lymphoma models for B cell activation and tolerance, J. Exp. Med. 164: 156 (1986).PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1987

Authors and Affiliations

  • Sandra H. Bridges
    • 1
    • 2
  • Dan L. Longo
    • 3
  1. 1.Medicine Branch, National Cancer InstituteNational Institutes of HealthBethesdaUSA
  2. 2.Centro di Endocrinologia ed Oncologia del CNRNaplesItaly
  3. 3.Biological Response Modifiers Program, Division of Cancer TreatmentNational Cancer InstituteBethesdaUSA

Personalised recommendations